Authors: Overbosch, D Schilthuis, H Bienzle, U Behrens, RH Kain, KC Clarke, PD Toovey, S Knobloch, J Nothdurft, HD Shaw, D Roskell, NS Chulay, JD

Citation: D. Overbosch et al., Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: Results from a randomized, double-blind study, CLIN INF D, 33(7), 2001, pp. 1015-1021

Authors: Hogh, B Clarke, PD Camus, D Nothdurft, HD Overbosch, D Gunther, M Joubert, I Kain, KC Shaw, D Roskell, NS Chulay, JD

Citation: B. Hogh et al., Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study, LANCET, 356(9245), 2000, pp. 1888-1894

Authors: van der Berg, JD Duvenage, CSJ Roskell, NS Scott, TR

Citation: Jd. Van Der Berg et al., Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa, CLIN THER, 21(4), 1999, pp. 741-749

Authors: Sadler, BM Hanson, CD Chittick, GE Symonds, WT Roskell, NS

Citation: Bm. Sadler et al., Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults, ANTIM AG CH, 43(7), 1999, pp. 1686-1692

Authors: Sukwa, TY Mulenga, M Chisdaka, N Roskell, NS Scott, TR

Citation: Ty. Sukwa et al., A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (R) (atovaquone/proguanil) for the prophylaxis of malaria in Zambia, AM J TROP M, 60(4), 1999, pp. 521-525